Addressing The Unmet Medical Needs Of AMI Patients - $NBS

Addressing The Unmet Medical Needs Of AMI Patients - $NBS

NeoStem, Inc. (AMEX: NBS; Stock Twits: $NBS) is engaged in the development and manufacturing of cell-based therapies in the U.S.  Its January 2011 acquisition of Progenitor Cell Therapy, LLC ("PCT") is central to the Company's strategic mission of capturing the paradigm shift to cell therapy.


In Drug Discovery & Development magazine, Neostem's Chief Medical Officer, Andrew Pecora, MD, FACP, wrote an article...

Read the full article here: